Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-322: pirtobrutinib + venetoclax + rituximab versus venetoclax + rituximab in previously treated CLL/SLL
CTR20220733Phase 3Active
- Sponsor
- Loxo Oncology
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirtobrutinib, venetoclax, rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Loxo Oncology. Started Jul 2022; status: active.
02
Drugs
pirtobrutinibvenetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20220733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220733.